MediWound (MDWD) Competitors $17.84 -1.22 (-6.40%) Closing price 04:00 PM EasternExtended Trading$17.86 +0.02 (+0.08%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDWD vs. NRIX, ABUS, OCS, SNDL, GHRS, TBPH, PROK, VIR, KURA, and KALVShould you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Nurix Therapeutics (NRIX), Arbutus Biopharma (ABUS), Oculis (OCS), SNDL (SNDL), GH Research (GHRS), Theravance Biopharma (TBPH), ProKidney (PROK), Vir Biotechnology (VIR), Kura Oncology (KURA), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. MediWound vs. Its Competitors Nurix Therapeutics Arbutus Biopharma Oculis SNDL GH Research Theravance Biopharma ProKidney Vir Biotechnology Kura Oncology KalVista Pharmaceuticals MediWound (NASDAQ:MDWD) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings. Do analysts prefer MDWD or NRIX? MediWound currently has a consensus target price of $32.25, indicating a potential upside of 80.77%. Nurix Therapeutics has a consensus target price of $29.07, indicating a potential upside of 221.59%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than MediWound.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has more volatility & risk, MDWD or NRIX? MediWound has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500. Which has preferable valuation and earnings, MDWD or NRIX? MediWound has higher earnings, but lower revenue than Nurix Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediWound$20.22M9.54-$30.22M-$2.64-6.76Nurix Therapeutics$54.55M12.67-$193.57M-$2.61-3.46 Is MDWD or NRIX more profitable? MediWound has a net margin of -142.18% compared to Nurix Therapeutics' net margin of -234.57%. Nurix Therapeutics' return on equity of -45.26% beat MediWound's return on equity.Company Net Margins Return on Equity Return on Assets MediWound-142.18% -96.71% -39.73% Nurix Therapeutics -234.57%-45.26%-34.71% Does the media favor MDWD or NRIX? In the previous week, Nurix Therapeutics had 7 more articles in the media than MediWound. MarketBeat recorded 8 mentions for Nurix Therapeutics and 1 mentions for MediWound. MediWound's average media sentiment score of 1.89 beat Nurix Therapeutics' score of 1.10 indicating that MediWound is being referred to more favorably in the media. Company Overall Sentiment MediWound Very Positive Nurix Therapeutics Positive Do institutionals and insiders have more ownership in MDWD or NRIX? 46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Comparatively, 7.4% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryNurix Therapeutics beats MediWound on 11 of the 16 factors compared between the two stocks. Get MediWound News Delivered to You Automatically Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDWD vs. The Competition Export to ExcelMetricMediWoundMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$205.99M$2.84B$5.79B$10.15BDividend YieldN/A56.65%5.69%4.61%P/E Ratio-6.7623.5374.5925.92Price / Sales9.54534.57449.5483.33Price / CashN/A169.2537.0859.91Price / Book6.175.3712.156.29Net Income-$30.22M$32.95M$3.28B$270.85M7 Day Performance9.52%1.31%0.98%3.36%1 Month Performance-4.95%8.31%7.20%6.41%1 Year Performance1.31%0.29%63.06%28.26% MediWound Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDWDMediWound1.6388 of 5 stars$17.84-6.4%$32.25+80.8%+11.4%$205.99M$20.22M-6.7680Gap UpNRIXNurix Therapeutics2.3862 of 5 stars$9.34-0.7%$28.87+209.1%-61.3%$714.04M$54.55M-3.58300News CoveragePositive NewsHigh Trading VolumeABUSArbutus Biopharma2.034 of 5 stars$3.71+1.1%$5.50+48.2%+7.5%$711.20M$6.17M-12.7990News CoveragePositive NewsOCSOculis3.3025 of 5 stars$16.13-1.3%$35.75+121.6%+43.5%$704.28M$780K-6.042Short Interest ↓SNDLSNDL3.8409 of 5 stars$2.68-0.4%$4.00+49.3%+15.5%$704.24M$671.81M-9.932,516Positive NewsGHRSGH Research2.5362 of 5 stars$13.50-2.5%$32.00+137.0%+53.3%$702.38MN/A-18.2410TBPHTheravance Biopharma3.4808 of 5 stars$13.88-0.6%$21.33+53.7%+69.1%$699.02M$64.38M57.83110News CoveragePositive NewsAnalyst ForecastShort Interest ↑PROKProKidney3.5424 of 5 stars$2.36-5.6%$6.25+164.8%+24.2%$694.51M$80K-4.143News CoveragePositive NewsVIRVir Biotechnology3.25 of 5 stars$4.94-2.0%$28.44+475.8%-33.2%$686.25M$74.21M-1.24580KURAKura Oncology4.3181 of 5 stars$7.90-2.1%$24.10+205.1%-55.6%$685.70M$53.88M-3.50130Positive NewsInsider TradeKALVKalVista Pharmaceuticals4.0313 of 5 stars$13.46-0.4%$26.29+95.3%+38.2%$677.57MN/A-3.65100Trending NewsEarnings ReportAnalyst ForecastInsider Trade Related Companies and Tools Related Companies Nurix Therapeutics Alternatives Arbutus Biopharma Alternatives Oculis Alternatives SNDL Alternatives GH Research Alternatives Theravance Biopharma Alternatives ProKidney Alternatives Vir Biotechnology Alternatives Kura Oncology Alternatives KalVista Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDWD) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediWound With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
